By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is generally neutral to bearish on the nuclear sector, with concerns about extreme valuations (BWXT at 53x forward P/E, CCJ at 120x) given modest market projections and historical risks such as regulatory delays and uranium price volatility.
Risk: Extreme valuations that assume flawless execution in a sector plagued by regulatory delays and supply chain bottlenecks.
Opportunity: The potential of Small Modular Reactors (SMRs) to shift the valuation from utility-like to high-growth industrial tech, if regulatory hurdles can be overcome.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Companies and countries alike are looking for more power.
The global nuclear industry is small but growing.
BWX Technologies and Cameco are two stocks worth considering.
Nuclear power has been making headlines in April. From potentially putting nuclear reactors in outer space to Japan opening a new reactor to Eli Lilly potentially collaborating with Indiana on nuclear power projects, the topic is everywhere. As countries and companies look to secure their power needs, they're open to nuclear options.
There are a few different ways to invest in the industry. Two companies worth digging in on are BWX Technologies (NYSE: BWXT) and Cameco (NYSE: CCJ).
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Before looking at the two stocks, I want to go over the projected market size. Fortune Business has projected that the global nuclear energy market would reach $41.6 billion in 2026, climbing to $52.6 billion by 2034. For another estimate, MarketandMarkets projects it will be a $44.7 billion market by 2029.
That shows that, while the market is expected to expand, it may not be as rapidly as some are anticipating.
The first company to consider is BWX Technologies, which does everything from manufacturing nuclear reactors and components to developing nuclear technology to be used in outer space.
As evidenced by its revenue, the company is seeing increased demand for its services. In 2025, BWX reported full-year revenue of $3.2 billion. It expects that to climb to $3.7 billion for 2026. It also announced on April 20 that it entered into a definitive agreement to acquire Precision Components Group, which BWX says will expand its "heavy-manufacturing footprint and establish additional U.S. commercial nuclear production capacity to serve growing domestic demand."
BWX is valued like a high-growth stock, with a forward price-to-earnings (P/E) ratio of 53, so lots of growth is already priced in. It also pays a dividend, which yields 0.4%.
The second stock to consider is Cameco, which calls itself "one of the largest global providers of uranium fuel" in the world. It does everything from exploration to mining to conversion.
Like BWX, it's seeing demand increase in its respective business. It reported revenue of $3.4 billion in 2025, up from $3.1 billion in 2024. It also reported gross profit increasing from $783 million in 2024 to $970 million in 2025.
This is also not a stock for a value investor, as there are sky-high expectations around the company. Its forward P/E is 120, nearly double what it was at the end of December 2025. It offers a dividend payout that yields roughly 0.1%, making it a company to mainly own for stock price appreciation potential.
Before you buy stock in BWX Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BWX Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of April 26, 2026. *
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BWX Technologies and Cameco. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The current valuations for BWXT and CCJ have already priced in a decade of flawless growth, leaving zero margin of safety for operational or regulatory setbacks."
The article captures the 'nuclear renaissance' narrative but ignores the brutal reality of valuation. A forward P/E of 53 for BWXT and 120 for CCJ represents extreme optimism that assumes flawless execution in a sector plagued by regulatory delays, supply chain bottlenecks, and massive capital expenditure requirements. While the thesis of nuclear as a baseload power solution for AI data centers is sound, investors are paying for perfection. At these multiples, any hiccup in government contracting or uranium spot price volatility will lead to significant multiple compression. I am neutral on the sector; the growth is real, but the entry prices are dangerous.
If nuclear energy becomes the only viable path to satisfy the massive power demands of hyperscalers, these companies effectively become the 'utilities' of the AI age, justifying premium multiples similar to software-as-a-service providers.
"BWXT and CCJ's sky-high forward P/Es (53x and 120x) embed perfection in a nuclear sector with modest projected growth and execution risks."
Nuclear demand is real—AI data centers and baseload power needs are driving it—but the article's modest market projections ($41.6B in 2026 to $52.6B by 2034, ~3% CAGR) clash with BWXT's 53x forward P/E (on ~16% revenue growth to $3.7B) and CCJ's absurd 120x (despite solid gross profit gains). BWXT's acquisition adds capacity, but regulatory delays and uranium supply ramps (new mines online) cap upside. High multiples price in flawless execution amid historical nuclear overruns; I'd wait for pullbacks.
If AI hyperscalers commit to nuclear PPAs at scale and uranium shortages persist longer than expected, these valuations could prove cheap as EPS growth accelerates beyond forecasts.
"Both stocks are priced for 20%+ annual growth in a market growing 5% CAGR; sentiment has decoupled from the actual addressable market."
The article conflates sentiment with fundamentals. Yes, nuclear is trendy—Eli Lilly mentions, space reactors, Japan reopening plants. But the market projections are underwhelming: $41.6B by 2026 growing to $52.6B by 2034 is ~5% CAGR, barely above inflation. CCJ trades at 120x forward P/E; BWXT at 53x. Both are pricing in a nuclear renaissance that the addressable-market data doesn't support. BWXT's Precision Components acquisition is sensible, but $3.2B→$3.7B revenue growth (15.6%) doesn't justify 53x multiples if margins don't expand materially. The article provides zero margin analysis or capex intensity.
If regulatory tailwinds accelerate (EU taxonomy shifts, U.S. production tax credits expand), and AI data centers drive a genuine power crisis, nuclear could be capacity-constrained for a decade, justifying premium multiples on near-term scarcity value rather than long-term market size.
"Valuations price in optimistic growth; any delay in reactor rollouts or a drop in uranium prices could cause sharp multiple compression."
The piece frames nuclear as a growing, underappreciated market with BWX Technologies (BWXT) and Cameco (CCJ) as picks. BWXT shows growth signals (2025 revenue ~$3.2B; 2026 guidance ~$3.7B) plus an acquisition, while Cameco reports rising 2025 gross profit. Yet both names carry extreme valuations: BWXT ~53x forward P/E with 0.4% yield; Cameco ~120x forward P/E with ~0.1% yield. The article glosses over major risks: multi-year, capex-intensive reactor-build cycles; uranium price volatility; regulatory and geopolitical risk; and a potentially modest total market size that could disappoint, triggering multiple compressions if near-term demand stalls.
The strongest case against this bearish read is that policy support and secular demand for clean energy could trigger a protracted, high-price environment for uranium and a faster-than-expected nuclear buildup, justifying rich valuations. If reactors come online on schedule and capex financing remains accessible, these stocks could re-rate meaningfully.
"The market is pricing BWXT for SMR-driven disruption rather than traditional utility-scale nuclear growth."
Claude, you’re right to highlight the disconnect between the 5% CAGR and these P/E multiples, but you're missing the 'SMR' (Small Modular Reactor) wildcard. BWXT isn't just a legacy component maker; they are positioning for micro-reactors that don't follow the traditional, failed 10-year, multi-billion dollar build cycle. If the NRC streamlines licensing for these units, the TAM isn't just 'nuclear power,' it's 'distributed energy for hyperscalers.' That shifts the valuation from utility-like to high-growth industrial tech.
"BWXT's SMR/micro-reactor efforts remain pre-commercial with proven historical failure risks, not a valuation justification."
Gemini, SMRs aren't the deus ex machina you suggest—NuScale's $9B+ Carbon Free Power Project collapsed in 2023 after years of delays and cost overruns, with only prototypes to show. BWXT's Project Pele micro-reactor is DoD-funded but years from commercial hyperscaler deployment. This reinforces, not shifts, the capex and regulatory risks everyone flags, keeping 53x P/E frothy.
"BWXT's valuation hinges on whether DoD success translates to commercial hyperscaler deployment—the article provides zero evidence either way."
Grok's NuScale precedent is damning, but conflates prototype risk with commercial viability. BWXT's Project Pele is DoD-funded (de-risked capex), not VC-backed. The real question: does DoD deployment prove scalability to hyperscalers, or does it remain a niche government contract? If the former, BWXT's 53x P/E reflects optionality on a $100B+ distributed-energy TAM, not legacy nuclear. If the latter, Grok's frothy thesis holds. The article never distinguishes between these paths.
"SMR optionality via DoD funding could unlock a long runway, but without commercial hyperscaler uptake the current valuations are fragile."
Responding to Grok: NuScale-like failures aren’t destiny for BWXT’s Pele path, but they underscore execution and regulatory risk in SMRs. The DoD-funded angle could de-risk capex and unlock a separate, longer runway of demand; if that handoff to hyperscalers never materializes, the current price is purely speculative optionality. My stance remains cautious: optionality exists, but the risk that capex/regulatory hurdles stay material is not priced away.
The panel is generally neutral to bearish on the nuclear sector, with concerns about extreme valuations (BWXT at 53x forward P/E, CCJ at 120x) given modest market projections and historical risks such as regulatory delays and uranium price volatility.
The potential of Small Modular Reactors (SMRs) to shift the valuation from utility-like to high-growth industrial tech, if regulatory hurdles can be overcome.
Extreme valuations that assume flawless execution in a sector plagued by regulatory delays and supply chain bottlenecks.